Dr. Michael E. Lytton was appointed as Executive Vice President Corporationrationrate Development and Strategy, General Counsel of Patheon Inc ., with effect from May 11, 2011. Most recently, from January 2009 through February 2011, Mr. Lytton supported Biogen?s growth by its corporate development team that refined and executed its corporate partnership strategy, including the inlicensing of several latestage molecules. Prior to joining Biogen, from January 2001 through December 2008, Mr. Lytton was a General Partner with Oxford Bioscience Partners, a VC firm investing in therapeutic, diagnostic and life science tool companies. Prior to Oxford, Mr. Lytton practiced law for 17 years and specialized in representing biomedical companies; he is a past Partner and member of the Executive Committee of the law firm Edwards Angell Palmer & Dodge and previously was a Partner of the law firm Hale and Dorr . From September 2004 to October 2011, Mr. Lytton was the Chairman of the Board of Santhera Pharmaceuticals AG, and he has also served on various boards of many other academic, nonprofit and private and public forprofit companies throughout his career
Executive Vice President - Corporate Development and Strategy, General Counsel
Age: 55 President Since 2011
|Lytton holds an undergraduate degree from Princeton University, a MS degree in Epidemiology from the London School of Hygiene and Tropical Medicine at the University of London, U.K. where he was a Fulbright Scholar, and a Juris Doctor from Harvard Law School.|
The company has return on total asset (ROA) of 3.86 % which means that it generated profit of $3.86 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of (85.87) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 589.6 M in total debt with debt to equity ratio (D/E) of 5.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Patheon Inc has Current Ratio of 1.69 which is within standard range for the sector.
Entity SummaryPatheon Inc. offer drug development and manufacturing services to the pharmaceutical, biotechnology, and specialty pharmaceutical companies worldwide. Patheon Inc [PTI] is traded on Toronto Stock Exchange in Canada. It is located in Mississauga, ON LN K and employs 4,700 people. Filter other
|Click to run this filter|| |
Filter Other Insiders
| PTI Toronto #2731579CA
Benchmark S&P 500
Currency: CAD - Canadian Dollar
Traded on Toronto Stock Exchange
Patheon Inc has less than 47.0 (%) percent chance of experiencing financial distress in the next 2 years of operations.
Patheon price boundaries
Promote Patheon and Michael Lytton